Frequency distribution of NAT2 genotype and alleles and deduced phenotype (according to the NAT-2 nomenclature; http://louisville.edu/medschool/pharmacology/NAT2.html) between patients who developed concomitant efavirenz based ARV and rifampicin based anti-tuberculosis drug induced liver injury (DILI Yes) and who did not (DILI No). Here, NAT2 is linked to tuberculosis.